FDA Approves Enhertu and Combo Treatments as First-Line Breast Cancer Therapies
TL;DR Summary
The FDA has approved AstraZeneca and Daiichi Sankyo's drug Enhertu, in combination with Roche's Perjeta, as a first-line treatment for advanced HER2-positive breast cancer, based on a study showing improved progression-free survival and tumor response.
- AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment Reuters
- AZ, Daiichi score with FDA nod for Enhertu combo in 1st-line breast cancer Fierce Pharma
- FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer OncLive
- FDA greenlights Enhertu's move into first-line breast cancer FirstWord Pharma
- Enhertu® plus pertuzumab approved in the US marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
89%
316 → 35 words
Want the full story? Read the original article
Read on Reuters